What happened with TLSI today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
TriSalus Life Sciences makes TriNav, an FDA-cleared catheter system used mainly in embolization procedures for liver cancer and cancers that have spread to the liver. Its self-expanding SmartValve changes pressure and flow during delivery, aiming to direct treatment particles or drugs more evenly toward tumors and limit delivery to healthy tissue.
Hospitals and ambulatory surgery centers buy TriNav through the company’s direct sales team, which works with the interventional radiologists performing these procedures. TriNav supplies nearly all revenue, so the business depends heavily on physicians choosing it and on insurance reimbursement that makes its use affordable for healthcare providers.
TriSalus also develops nelitolimod, an investigational cancer drug in early clinical development. It is seeking partners to fund further development. Nelitolimod generates no product revenue and is not approved for sale in any jurisdiction; commercialization requires successful development and regulatory approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
TriSalus’s results hinge on TriNav adoption and reimbursement in liver embolization, where standard microcatheters and privately held Embolix’s Sniper also compete.
Merit Medical competes for the interventional radiologists choosing devices for tumor-directed procedures: its Swift NINJA microcatheter is an alternative to TriSalus’s TriNav, which hospitals and surgery centers buy. Watch Merit’s microcatheter product launches for changes in the choices available to those doctors.
RenovoRx competes with TriSalus in selling cancer centers devices that use pressure to deliver treatment through arteries, while both develop localized treatments for solid tumors. Watch repeat orders and new U.S. cancer-center customers for RenovoCath, which pushes chemotherapy across the arterial wall near a tumor, as signs of uptake of this competing approach.
Boston Scientific has two ties to TriSalus: it sells microcatheters that compete with TriNav for hospital purchases, and TheraSphere products that deliver radiation in the liver-cancer procedures TriNav supports. Watch TheraSphere news for developments in the same treatment market, rather than treating all of Boston Scientific’s business as a rival.
AngioDynamics offers tumor-destroying ablation systems to the same interventional clinicians who choose catheter-directed cancer treatments using TriSalus devices bought by hospitals and surgery centers. Watch developments in its NanoKnife and Solero ablation products for changes in the treatment alternatives available to those clinicians.
Boston Scientific Corp. earningsBSX
Boston Scientific's report can show whether its TheraSphere liver-cancer treatment business is active in the procedure market TriNav supports, rather than treating all of Boston Scientific as a TriSalus rival.
Look for disclosures on TheraSphere use or demand in liver-cancer procedures. Stronger activity would suggest demand remains in the treatment market TriNav serves; weaker activity would point to a possible cooling in that market. Boston Scientific's results do not directly establish whether TriNav catheter sales rose or fell.
Fed Interest Rate Decision
The Fed’s rate decision signals the direction of borrowing costs, which can change the interest TriSalus pays on its SOFR-linked OrbiMed debt.
Expected4.0%Last release4.0%
If it comes in above expectations
If rates rise, TriSalus may pay more interest on its repricing OrbiMed debt, although the debt’s 4% SOFR floor limits the effect of rate declines, not increases.
If it comes in below expectations
If rates fall, TriSalus may pay less interest as its OrbiMed debt reprices, but the 4% SOFR floor can limit the reduction if SOFR is already near or below that level.
Merit Medical Systems Inc earningsMMSI
Merit Medical's microcatheters compete with TriNav for interventional radiologists' choices, and its report can show whether doctors are getting more alternatives.
Watch Merit Medical's disclosures about microcatheter launches and adoption. More launches or wider adoption would give hospitals and physicians more alternatives to weigh against TriNav, increasing potential competitive pressure; no such progress would offer no new evidence of a widening choice set, but would not show that TriNav won orders.
TriSalus Life Sciences, Inc. earningsThis company
TriSalus gets nearly all its revenue from TriNav catheters, and this report will show whether manufacturing costs are eating into gross profit as hospitals and surgery centers buy more.
Read TriNav sales alongside gross margin, the share of sales left after product costs. Rising sales with a steady margin would show that more catheters are bringing in revenue without further manufacturing-efficiency slippage. Rising sales with a falling margin would mean added volume is not yet converting cleanly into gross profit, so the expected benefit from scaling production remains unproven.
RenovoRx, Inc. earningsRNXT
RenovoRx's RenovoCath delivers chemotherapy through an artery near a tumor, and its report can show whether cancer centers are adopting this alternative to procedures using TriNav.
Read repeat RenovoCath orders alongside new U.S. cancer-center customers. Growth in both would show that more centers are returning to this localized delivery approach, making it a more established competing treatment path for TriSalus; little progress on either would leave that competitive threat less supported by adoption evidence.
